#ASH18: Gilead posts im­pres­sive sur­vival rates for Yescar­ta — but sales re­main lean

A lit­tle more than a year af­ter Yescar­ta was ap­proved as the first CAR-T for third-line ther­a­py in large B-cell lym­phoma, re­searchers are still try­ing to de­ter­mine what the me­di­an over­all sur­vival rate for pa­tients is. It hasn’t been reached.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER